Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DOT1L | Q8TEK3 | 3/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | DPP4 | P27487 | 1/20 | 0.81 |
| ▸ | MEN1 | O00255 | 1/20 | 0.81 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.81 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.81 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.81 |
| ▸ | GAPDH | P04406 | 1/20 | 0.81 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.81 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.81 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.81 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.81 |
| ▸ | STAT6 | P42226 | 1/20 | 0.81 |
| ▸ | PI4KA | P42356 | 1/20 | 0.81 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.81 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.81 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.81 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.81 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.81 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL836051 | 1.00 | DOT1L (0.81) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL874448 | 1.00 | DOT1L (0.81) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL8332213 | 1.00 | DOT1L (0.81) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL506313 | 1.00 | DOT1L (0.81) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| Phosphoric Acid SCHEMBL1972743 | 0.94 | P2RY1 (0.75) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| Adenosine SCHEMBL6674206 | 0.91 | ADORA3 (0.97) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL13834962 | 0.90 | ADORA3 (0.82) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL28668199 | 0.90 | DOT1L (0.78) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL13834960 | 0.90 | ADORA3 (0.82) | DOT1LADORA3DPP4MEN1SLC28A1 | |
| SCHEMBL13834964 | 0.90 | ADORA3 (0.82) | DOT1LADORA3DPP4MEN1SLC28A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170095497-A1 | TRANSIENT INHIBITION OF ADENOSINE KINASE AS AN ANTI-EPILEPTOGENESIS TREATMENT | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2017-04-06 | — | — | US | claimed |
| US-20140112906-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-04-24 | — | — | US | claimed |
| US-20140112905-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-04-24 | — | — | US | claimed |
| US-20130209438-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-08-15 | — | — | US | claimed |
| US-20100266569-A1 | PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2010-10-21 | — | — | US | claimed |
| EP-2219666-A1 | PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN | The University of North Carolina At Chapel Hill (US) | 2010-08-25 | — | — | EP | claimed |
| US-20090137662-A1 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-05-28 | — | — | US | claimed |
| WO-2009064497-A1 | PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2009-05-22 | — | — | WO | claimed |
| US-20090047214-A1 | Novel methylation marker | ONCOMETHYLOME SCIENCES S.A. | 2009-02-19 | — | — | US | claimed |
| US-6958318-B2 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION (US) | 2005-10-25 | — | — | US | claimed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | claimed |
| US-20030228576-A1 | Nucleotide sequence coding for a cleaving enzyme; can use in conjuction with substrate to produce toxins which impair abnormal cell growth; antitumor agents | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2003-12-11 | — | — | US | claimed |
| EP-0715523-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | UAB RESEARCH FOUNDATION (US) | 2002-12-18 | — | — | EP | claimed |
| US-6491905-B1 | GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY | THE UAB RESEARCH FOUNDATION | 2002-12-10 | — | — | US | claimed |
| US-6258794-B1 | ANTIDEPRESSANTS AND COMPOUNDS THAT INHIBIT ADENOSINE UPTAKE | THE MCLEAN HOSPITAL CORPORATION | 2001-07-10 | — | — | US | claimed |
| WO-2001044265-A1 | TREATMENT OF MENTAL CONDITIONS INCLUDING DEPRESSION | THE MCLEAN HOSPITAL CORPORATION (US) | 2001-06-21 | — | — | WO | claimed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | claimed |
| EP-0715523-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1996-06-12 | — | — | EP | claimed |
| WO-1995007718-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1995-03-23 | — | — | WO | claimed |
| US-20250137070-A1 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | EXACT SCIENCES CORP (US) | 2025-05-01 | — | — | US | disclosed |
| US-20250092464-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | EXACT SCIENCES CORPORATION | 2025-03-20 | — | — | US | disclosed |
| US-20250084487-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | EXACT SCIENCES CORPORATION | 2025-03-13 | — | — | US | disclosed |
| US-12215389-B2 | Compositions for detecting epigenetic modifications | EXACT SCIENCES CORPORATION (US) | 2025-02-04 | — | — | US | disclosed |
| US-20250034653-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | JPMORGAN CHASE BANK, N.A. | 2025-01-30 | — | — | US | disclosed |
| US-20240318260-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | EXACT SCIENCES CORPORATION | 2024-09-26 | — | — | US | disclosed |
| US-11987848-B2 | Fecal sample processing and analysis comprising detection of blood | EXACT SCIENCES CORPORATION (US) | 2024-05-21 | — | — | US | disclosed |
| US-11970746-B2 | Fecal sample processing and analysis comprising detection of blood | EXACT SCIENCES CORPORATION (US) | 2024-04-30 | — | — | US | disclosed |
| US-11845991-B2 | Fecal sample processing and analysis comprising detection of blood | EXACT SCIENCES CORPORATION (US) | 2023-12-19 | — | — | US | disclosed |
| US-20230313317-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | JPMORGAN CHASE BANK, N.A. | 2023-10-05 | — | — | US | disclosed |
| US-20230272488-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | JPMORGAN CHASE BANK, N.A. | 2023-08-31 | — | — | US | disclosed |
| US-11634781-B2 | Fecal sample processing and analysis comprising detection of blood | JPMORGAN CHASE BANK, N.A. | 2023-04-25 | — | — | US | disclosed |
| US-20230102924-A1 | Methods of Treating Cancer Using Checkpoint Inhibitors in Combination with Purine Cleaving Enzymes | UNIV EMORY (US) | 2023-03-30 | — | — | US | disclosed |
| US-20230048152-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | JPMORGAN CHASE BANK, N.A. | 2023-02-16 | — | — | US | disclosed |
| US-20220064740-A1 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | JPMORGAN CHASE BANK, N.A. | 2022-03-03 | — | — | US | disclosed |
| US-11149317-B2 | Methods for detecting epigenetic modifications | EXACT SCIENCES DEVELOPMENT COMPANY, LLC (US) | 2021-10-19 | — | — | US | disclosed |
| EP-3831372-A1 | MITOGUAZONE FOR PREVENTING THE RELAPSE OR THE PROGRESSION OF MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2021-06-09 | — | — | EP | disclosed |
| US-10808286-B2 | Methods for detecting epigenetic modifications | EXACT SCIENCES DEVELOPMENT COMPANY, LLC (US) | 2020-10-20 | — | — | US | disclosed |
| EP-3434791-B1 | EPIGENETIC CHANGE IN SELECTED GENES AND CANCER | EXACT SCIENCES DEV CO LLC (US) | 2020-05-27 | — | — | EP | disclosed |
| US-20190276900-A1 | FECAL SAMPLE PROCESSING AND ANALYSIS COMPRISING DETECTION OF BLOOD | EXACT SCIENCES CORPORATION | 2019-09-12 | — | — | US | disclosed |
| EP-3473247-A1 | COMPOSITION FOR ORAL DELIVERY COMPRISING MGBG FOR USE IN TREATING MULTIPLE SCLEROSIS | Pathologica LLC (US) | 2019-04-24 | — | — | EP | disclosed |
| US-20190032149-A1 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | JPMORGAN CHASE BANK, N.A. | 2019-01-31 | — | — | US | disclosed |
| EP-3434791-A1 | EPIGENETIC CHANGE IN SELECTED GENES AND CANCER | Exact Sciences Development Company, LLC (US) | 2019-01-30 | — | — | EP | disclosed |
| EP-2453886-B1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2018-12-12 | — | — | EP | disclosed |
| EP-2331115-B3 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RES FOUND (US) | 2018-12-05 | — | — | EP | disclosed |
| US-20180327859-A1 | METHODS FOR DETECTING EPIGENETIC MODIFICATIONS | JPMORGAN CHASE BANK, N.A. | 2018-11-15 | — | — | US | disclosed |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | PATHOLOGICA LLC (US) | 2018-10-02 | — | — | US | disclosed |
| US-10053724-B2 | Methylation detection of the MGMT promoter | MDXHEALTH SA (BE) | 2018-08-21 | — | — | US | disclosed |
| EP-2069527-B1 | EPIGENETIC CHANGE IN SELECTED GENES AND CANCER | EXACT SCIENCES DEV CO LLC (US) | 2018-06-06 | — | — | EP | disclosed |
| US-9982308-B2 | Methods for amplifying DNA from the promoter of the NDRG4 gene DNA obtained from a fecal sample | EXACT SCIENCES DEVELOPMENT COMPANY, LLC (US) | 2018-05-29 | — | — | US | disclosed |
| US-20170298448-A1 | METHODS FOR DETECTING COLORECTAL CANCER | JPMORGAN CHASE BANK, N.A. | 2017-10-19 | — | — | US | disclosed |
| EP-2707483-B1 | METHODS AND MATERIALS FOR NUCLEIC ACID MANIPULATION | RWTH AACHEN UNIV (DE) | 2017-10-18 | — | — | EP | disclosed |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA, LLC | 2017-10-12 | — | — | US | disclosed |
| US-9616035-B2 | Pharmaceutical for oral delivery comprising MGBG and methods of treating disease | PATHOLOGICA, LLC (US) | 2017-04-11 | — | — | US | disclosed |
| US-20170095497-A1 | TRANSIENT INHIBITION OF ADENOSINE KINASE AS AN ANTI-EPILEPTOGENESIS TREATMENT | LEGACY EMANUEL HOSPITAL & HEALTH CENTER (US) | 2017-04-06 | — | — | US | disclosed |
| EP-3150220-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | The UAB Research Foundation (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-1373185-B1 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | AMINEX THERAPEUTICS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2650377-B1 | Epigenetic change in selected genes and cancer | MDXHEALTH SA (BE) | 2016-12-21 | — | — | EP | disclosed |
| EP-2331115-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | UAB RESEARCH FOUNDATION (US) | 2016-10-05 | — | — | EP | disclosed |
| US-9388471-B2 | Methylation of the GATA4 gene in urine samples as a marker for bladder cancer detection | MDXHEALTH SA (BE) | 2016-07-12 | — | — | US | disclosed |
| US-20160194723-A1 | Systems, Kits, and Tests for Detecting Colorectal Cancer | MDXHEALTH SA (BE) | 2016-07-07 | — | — | US | disclosed |
| EP-2406393-B1 | NOVEL MARKERS FOR BLADDER CANCER DETECTION | MDXHEALTH SA (BE) | 2016-05-04 | — | — | EP | disclosed |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | NORTHEASTERN UNIVERSITY | 2016-03-10 | — | — | US | disclosed |
| US-20160032368-A1 | METHYLATION DETECTION | MDXHEALTH SA (BE) | 2016-02-04 | — | — | US | disclosed |
| US-20160022784-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | CORNELL UNIVERSITY | 2016-01-28 | — | — | US | disclosed |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA, LLC | 2015-12-17 | — | — | US | disclosed |
| EP-2943189-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | Pathologica LLC (US) | 2015-11-18 | — | — | EP | disclosed |
| US-20150323542-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2015-11-12 | — | — | US | disclosed |
| US-20150322107-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | CAYMAN CHEMICAL COMPANY, INCORPORATED | 2015-11-12 | — | — | US | disclosed |
| US-9120820-B2 | Fluorescent molecular probes for use in assays that measure test compound competitive binding with SAM-utilizing proteins | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2015-09-01 | — | — | US | disclosed |
| US-20150240318-A1 | Methods for Detecting Epigenetic Modifications | MDXHEALTH SA (BE) | 2015-08-27 | — | — | US | disclosed |
| US-9050280-B2 | Methylation detection of MGMT | MDXHEALTH SA (BE) | 2015-06-09 | — | — | US | disclosed |
| US-20150119351-A1 | THERAPY OF TUMORS AND INFECTIOUS AGENTS DEFICIENT IN METHYLTHIOADENOSINE PHOSPHORYLASE | LUBIN ADAM (US) | 2015-04-30 | — | — | US | disclosed |
| US-8969046-B2 | Methods for detecting epigenetic modifications | MDXHEALTH SA (BE) | 2015-03-03 | — | — | US | disclosed |
| US-8927520-B2 | Antibacterial compounds | INSTITUT PASTEUR (FR) | 2015-01-06 | — | — | US | disclosed |
| US-8883500-B2 | Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapy | NORTHEASTERN UNIVERSITY (US) | 2014-11-11 | — | — | US | disclosed |
| EP-2201131-B1 | IMPROVED METHYLATION DETECTION | MDXHEALTH SA (BE) | 2014-11-05 | — | — | EP | disclosed |
| US-8796241-B2 | Therapy of tumors and infectious agents deficient in methylthioadenosine phosphorylase | LUBIN ADAM (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140199285-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | SOUTHERN RESEARCH INSTITUTE (US) | 2014-07-17 | — | — | US | disclosed |
| WO-2014110154-A1 | METHODS AND COMP0STIONS FOR TREATMENT OF DEMYELINATING DISEASES | PATHOLOGICA LLC (US) | 2014-07-17 | — | — | WO | disclosed |
| US-20140112905-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140112906-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2014-04-24 | — | — | US | disclosed |
| US-20130331351-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | INSTITUT PASTEUR (FR) | 2013-12-12 | — | — | US | disclosed |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | SITKOVSKY MICHAIL V (US) | 2013-12-05 | — | — | US | disclosed |
| EP-2471804-B1 | Diadenosine antibacterial compounds | PASTEUR INSTITUT (FR) | 2013-11-06 | — | — | EP | disclosed |
| EP-2658863-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | INSTITUT PASTEUR (FR) | 2013-11-06 | — | — | EP | disclosed |
| EP-2650377-A1 | Epigenetic change in selected genes and cancer | MDxHealth SA (BE) | 2013-10-16 | — | — | EP | disclosed |
| US-8513267-B2 | 4-anilinoquinazoline derivatives with adenosine-kinase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2013-08-20 | — | — | US | disclosed |
| US-20130209438-A1 | Prostatic Acid Phosphatase for the Treatment of Pain | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-08-15 | — | — | US | disclosed |
| EP-2608794-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | Northeastern University (US) | 2013-07-03 | — | — | EP | disclosed |
| US-20120295311-A1 | Methods and Materials for Nucleic Acid Manipulation | BASF SE (DE) | 2012-11-22 | — | — | US | disclosed |
| US-20120295283-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2012159072-A2 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | CAYMAN CHEMICAL COMPANY, INCORPORATED (US) | 2012-11-22 | — | — | WO | disclosed |
| US-8258186-B2 | Pharmaceutical for oral delivery comprising MGBG | PATHOLOGICA, LLC (US) | 2012-09-04 | — | — | US | disclosed |
| WO-2012090136-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | INSTITUT PASTEUR (FR) | 2012-07-05 | — | — | WO | disclosed |
| EP-2471804-A1 | Diadenosine antibacterial compounds | Institut Pasteur (FR) | 2012-07-04 | — | — | EP | disclosed |
| US-20120164238-A1 | METHODS OF DETECTING COLORECTAL CANCER | MDXHEALTH SA | 2012-06-28 | — | — | US | disclosed |
| EP-2453886-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | Pathologica, LLC. (US) | 2012-05-23 | — | — | EP | disclosed |
| US-RE43327-E1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20120094947-A1 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2012-04-19 | — | — | US | disclosed |
| US-8158376-B2 | Bisubstrate fluorescent probe binding to protein kinases | UNIVERSITY OF TARTU (EE) | 2012-04-17 | — | — | US | disclosed |
| US-8143375-B2 | Aziridine aldehydes, aziridine-conjugated amino derivatives, aziridine-conjugated biomolecules and processes for their preparation | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-03-27 | — | — | US | disclosed |
| WO-2012027695-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | NORTHEASTERN UNIVERSITY (US) | 2012-03-01 | — | — | WO | disclosed |
| US-20120027870-A1 | Novel Markers for Bladder Cancer Detection | MSxHealth SA (BE) | 2012-02-02 | — | — | US | disclosed |
| EP-2406393-A1 | NOVEL MARKERS FOR BLADDER CANCER DETECTION | MDxHealth SA (BE) | 2012-01-18 | — | — | EP | disclosed |
| EP-1737832-B1 | 4-ANILINOQUINAZOLINE DERIVATIVES WITH ADENOSINE-KINASE INHIBITORY PROPERTIES | UNICAMP (BR) | 2011-12-14 | — | — | EP | disclosed |
| US-20110287416-A1 | METHYLATION DETECTION | ONCOMETHYLOME SCIENCES SA (BE) | 2011-11-24 | — | — | US | disclosed |
| US-20110212073-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE AS ENZYMATIC ACTIVATOR OF NUCLEOSIDE PRODRUGS | THE UAB RESEARCH FOUNDATION (US) | 2011-09-01 | — | — | US | disclosed |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011009039-A2 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | PATHOLOGICA LLC (US) | 2011-01-20 | — | — | WO | disclosed |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | ZEALAND PHARMA A/S (DK) | 2010-12-16 | — | — | US | disclosed |
| US-20100266569-A1 | PROSTATIC ACID PHOSPHATASE FOR THE TREATMENT OF PAIN | NORTH CAROLINA AT CHAPEL HILL, THE UNIVERSITY OF | 2010-10-21 | — | — | US | disclosed |
| US-20100254965-A1 | Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction | BOARD OF REGENTS ,THE UNIVERSITY OF TEXAS SYSTEM | 2010-10-07 | — | — | US | disclosed |
| US-20100233743-A1 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | UNIVERSITY OF TARTU (EE) | 2010-09-16 | — | — | US | disclosed |
| WO-2010102823-A1 | NOVEL MARKERS FOR BLADDER CANCER DETECTION | ONCOMETHYLOME SCIENCES SA (BE) | 2010-09-16 | — | — | WO | disclosed |
| WO-2010089538-A2 | METHODS OF DETECTING COLORECTAL CANCER | ONCOMETHYLOME SCIENCES SA (BE) | 2010-08-12 | — | — | WO | disclosed |
| WO-2010065959-A1 | METHOD OF PREPARING ADENOSINE-RESISTANT ANTI-TUMOR T LYMPHOCYTES FOR ADOPTIVE IMMUNOTHERAPY | NORTHEASTERN UNIVERSITY (US) | 2010-06-10 | — | — | WO | disclosed |
| US-20100144836-A1 | Methods for Detecting Epigenetic Modifications | ONCOMETHYLOME SCIENCES SA (BE) | 2010-06-10 | — | — | US | disclosed |
| EP-2192905-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | Lubin, Adam (US) | 2010-06-09 | — | — | EP | disclosed |
| WO-2010020787-A1 | DIAGNOSIS AND TREATMENT OF TUMOURS | ONCOMETHYLOME SCIENCES SA (BE) | 2010-02-25 | — | — | WO | disclosed |
| WO-2010004251-A1 | DNA METHYLOMES | ONCOMETHYLOME SCIENCES SA (BE) | 2010-01-14 | — | — | WO | disclosed |
| US-20090275632-A1 | Methods of diagnosis and treatment | ONCOMETHYLOME SCIENCES SA | 2009-11-05 | — | — | US | disclosed |
| WO-2009086201-A1 | 2-5A ANALOGS AND THEIR USE AS ANTI-CANCER, ANTI-VIRAL AND ANTI- PARAS ITI C AGENTS | ALIOS BIOPHARMA, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
| EP-1844063-A4 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2009-06-17 | — | — | EP | disclosed |
| WO-2009071920-A2 | METHODS FOR IDENTIFYING EPIGENETICALLY SILENCED GENES AND NOVEL TUMOUR SUPPRESSOR GENES | ONCOMETHYLOME SCIENCES SA (BE) | 2009-06-11 | — | — | WO | disclosed |
| US-20090137662-A1 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2009-05-28 | — | — | US | disclosed |
| EP-2057279-A2 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | University of Tartu (EE) | 2009-05-13 | — | — | EP | disclosed |
| US-20090093424-A1 | Markers for melanoma | UNIVERSITY COLLEGE DUBLIN | 2009-04-09 | — | — | US | disclosed |
| WO-2009032057-A2 | METHOD FOR THE SELECTIVE THERAPY OF DISEASE | LUBIN ADAM (US) | 2009-03-12 | — | — | WO | disclosed |
| US-20090047214-A1 | Novel methylation marker | ONCOMETHYLOME SCIENCES S.A. | 2009-02-19 | — | — | US | disclosed |
| US-7488598-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY ENTERPRISE AND COMMERCIALIZATION (US) | 2009-02-10 | — | — | US | disclosed |
| US-7432302-B2 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2008-10-07 | — | — | US | disclosed |
| WO-2008066627-A2 | ADENOSINE SIGNALING IN DIAGNOSIS, TREATMENT AND PREVENTION OF PRIAPISM AND ERECTILE DYSFUNCTION | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2008-06-05 | — | — | WO | disclosed |
| WO-2008046232-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | YUDIN ANDREI K (CA) | 2008-04-24 | — | — | WO | disclosed |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | UTI LIMITED PARTNERSHIP (CA) | 2008-03-20 | — | — | US | disclosed |
| WO-2008019696-A2 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | UNIVERSITY OF TARTU (EE) | 2008-02-21 | — | — | WO | disclosed |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | IKARIA, INC. (US) | 2007-11-15 | — | — | US | disclosed |
| EP-1844063-A1 | PURINE NUCLEOSIDE ANALOGS | Uti Limited Partnership (CA) | 2007-10-17 | — | — | EP | disclosed |
| EP-1840227-A1 | Markers for melanoma | UNIVERSITY COLLEGE DUBLIN (IE) | 2007-10-03 | — | — | EP | disclosed |
| EP-1578931-A4 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS INC (US) | 2007-09-12 | — | — | EP | disclosed |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2007-03-15 | — | — | US | disclosed |
| EP-1737832-A1 | COMPOUNDS DERIVED FROM 4-ANILINEQUINAZOLINES WITH ADENOSINE-KINASE INHIBITOR PROPERTIES | UNIVERSIDADE ESTADUAL DE CAMPINAS - UNICAMP (BR) | 2007-01-03 | — | — | EP | disclosed |
| WO-2006081665-A1 | PURINE NUCLEOSIDE ANALOGS | UTI LIMITED PARTNERSHIP (CA) | 2006-08-10 | — | — | WO | disclosed |
| US-7037718-B2 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL RESEARCH FOUNDATION, INC. (US) | 2006-05-02 | — | — | US | disclosed |
| EP-1373185-A4 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS INC (US) | 2005-12-07 | — | — | EP | disclosed |
| US-6963010-B2 | Anticancer agents; osteoporosis; autoimmune disease | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-08 | — | — | US | disclosed |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-11-03 | — | — | US | disclosed |
| US-6958318-B2 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION (US) | 2005-10-25 | — | — | US | disclosed |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | CORNELL CENTER FOR TECHNOLOGY, ENTERPRISE & COIMMERCIALIZATION | 2005-09-29 | — | — | US | disclosed |
| EP-1578931-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | Rigel Pharmaceuticals, Inc. (US) | 2005-09-28 | — | — | EP | disclosed |
| WO-2005085213-A1 | COMPOUNDS DERIVED FROM 4-ANILINEQUINAZOLINES WITH ADENOSINE-KIASE INHIBITOR PROPERTIES | UNIVERSIDADE ESTADUAL DE CAMPINAS-UNICAMP (BR) | 2005-09-15 | — | — | WO | disclosed |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | MEDIQUEST THERAPEUTICS, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| EP-0836613-B1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2005-05-25 | — | — | EP | disclosed |
| EP-0832092-B1 | ORALLY ACTIVE ADENOSINE KINASE INHIBITORS | METABASIS THERAPEUTICS INC (US) | 2004-11-17 | — | — | EP | disclosed |
| WO-2004007680-A2 | METHODS OF IDENTIFYING COMPOUNDS THAT MODULATE IL-4 RECEPTOR-MEDIATED IGE SYNTHESIS UTILIZING AN ADENOSINE KINASE | RIGEL PHARMACEUTICALS, INC. (US) | 2004-01-22 | — | — | WO | disclosed |
| EP-0832091-B1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR INC (US) | 2004-01-14 | — | — | EP | disclosed |
| EP-1373185-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | Mediquest Therapeutics, Inc. (US) | 2004-01-02 | — | — | EP | disclosed |
| WO-2003082211-A2 | SYNERGY OF DOPAMINE D2 AND ADENOSINE A2 RECEPTORS ACTIVATES PKA SIGNALING VIA BETA/GAMMA DIMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2003-10-09 | — | — | WO | disclosed |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | AMINEX THERAPEUTICS, INC. | 2003-10-02 | — | — | US | disclosed |
| US-20030134819-A1 | Recombinant bacterial cells for delivery of PNP to tumor cells | SOUTHERN RESEARCH INSTITUTE | 2003-07-17 | — | — | US | disclosed |
| US-20030125298-A1 | Cancer therapy comprising deaminase enzyme inhibitors | CTRE DE RECHERCHE INDUST. DU QUEBEC (CA) | 2003-07-03 | — | — | US | disclosed |
| US-6579857-B1 | Combination cancer therapy comprising adenosine and deaminase enzyme inhibitors | EVANSTON NORTHWESTERN HEALTHCARE RESEARCH INSTITUTE | 2003-06-17 | — | — | US | disclosed |
| US-20030077268-A1 | Recombinant bacterial cells for delivery of PNP to tumor cells | THE UAB RESEARCH FOUNDATION | 2003-04-24 | — | — | US | disclosed |
| EP-0991412-B1 | AMINOACYL SULFAMIDES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS | CUBIST PHARM INC (US) | 2003-03-12 | — | — | EP | disclosed |
| EP-0715523-B1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | UAB RESEARCH FOUNDATION (US) | 2002-12-18 | — | — | EP | disclosed |
| US-6491905-B1 | GENETIC VECTORS COMPRISING DNA SEQUENCE CODES FROM ESCHERICHIA PURINE NUCLEOSIDE PHOSPHORYLASE (PNP), USED AS ANTICARCINOGENS IN COMBINATION WITH PURINE ANALOGUES AS PRODRUGS; GENE THERAPY | THE UAB RESEARCH FOUNDATION | 2002-12-10 | — | — | US | disclosed |
| EP-0755255-A4 | TREATMENT OF TOXOPLASMOSIS | RES CORP TECHNOLOGIES INC (US) | 2002-07-24 | — | — | EP | disclosed |
| WO-2002053519-A2 | HYDROPHOBIC POLYAMINE ANALOGS AND METHODS FOR THEIR USE | MEDIQUEST THERAPEUTICS, INC. (US) | 2002-07-11 | — | — | WO | disclosed |
| US-20020086835-A1 | Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2002-07-04 | — | — | US | disclosed |
| EP-1181019-A1 | USE OF ADENOSINE DEAMINASE INHIBITORS TO TREAT SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | Board of Trustees of the University of Illinois (US) | 2002-02-27 | — | — | EP | disclosed |
| EP-0873340-B1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | ABBOTT LAB (US) | 2001-11-21 | — | — | EP | disclosed |
| EP-0708781-B1 | A 3 ADENOSINE RECEPTOR AGONISTS | USA (US) | 2001-10-04 | — | — | EP | disclosed |
| WO-2001057040-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2001-08-09 | — | — | WO | disclosed |
| US-6258794-B1 | ANTIDEPRESSANTS AND COMPOUNDS THAT INHIBIT ADENOSINE UPTAKE | THE MCLEAN HOSPITAL CORPORATION | 2001-07-10 | — | — | US | disclosed |
| WO-2001044265-A1 | TREATMENT OF MENTAL CONDITIONS INCLUDING DEPRESSION | THE MCLEAN HOSPITAL CORPORATION (US) | 2001-06-21 | — | — | WO | disclosed |
| EP-1094818-A1 | USE OF TRICYCLIC ANTIDEPRESSANTS FOR LOCAL ANALGESIA | DALHOUSIE UNIVERSITY (CA) | 2001-05-02 | — | — | EP | disclosed |
| US-6211171-B1 | ADMINISTERING TRICYCLIC AMITRIPTYLINE AND DESIPRAMINE TO TREAT NEUROPATHIC PAIN | DALHOUSIE UNIVERSITY (CA) | 2001-04-03 | — | — | US | disclosed |
| WO-2000076524-A1 | COMBINATION CANCER THERAPY COMPRISING ADENOSINE AND DEAMINASE ENZYME INHIBITOR | EVANSTON NORTHWESTERN HEALTHCARE RESEARCH INSTITUTE (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-2000071127-A1 | USE OF ADENOSINE DEAMINASE INHIBITORS TO TREAT SYSTEMIC INFLAMMATORY RESPONSE SYNDROME | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-11-30 | — | — | WO | disclosed |
| US-6143749-A | Heterocyclic substituted cyclopentane compounds | ABBOTT LABORATORIES (US) | 2000-11-07 | — | — | US | disclosed |
| US-6103702-A | Use of adenosine deaminase inhibitors to treat systemic inflammatory response syndrome | BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-08-15 | — | — | US | disclosed |
| WO-2000023444-A1 | 5,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 2000-04-27 | — | — | WO | disclosed |
| EP-0989986-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO 2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | Abbott Laboratories (US) | 2000-04-05 | — | — | EP | disclosed |
| US-6030969-A | ADENOSINE KINASE INHIBITORS; ANTIISCHEMIA,-INFLAMMATORY, -DIABETIC AGENTS; NEUROLOGICAL AND GASTROINTESTINAL DISORDERS; NOCIPERCEPTION, IMMUNOSUPPRESSION; SEPSIS | ABBOTT LABORATORIES (US) | 2000-02-29 | — | — | US | disclosed |
| EP-0979230-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-16 | — | — | EP | disclosed |
| EP-0975633-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL 2,3-D]PYRIMIDINE COMPOUNDS | Abbott Laboratories (US) | 2000-02-02 | — | — | EP | disclosed |
| US-6017896-A | Purine nucleoside phosphorylase gene therapy for human malignancy | UNIVERSITY OF ALABAMA RESEARCH FOUNDATION AND SOUTHERN RESEARCH INSTITUTE (US) | 2000-01-25 | — | — | US | disclosed |
| EP-0684953-A4 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES. | GENSIA INC (US) | 1999-12-22 | — | — | EP | disclosed |
| EP-0496617-B1 | Adenosine kinase inhibitors | METABASIS THERAPEUTICS INC (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1999059598-A1 | USE OF TRICYCLIC ANTIDEPRESSANTS FOR LOCAL ANALGESIA | DALHOUSIE UNIVERSITY (CA) | 1999-11-25 | — | — | WO | disclosed |
| US-5864033-A | ENZYME INHIBITORS WITH HETEROCYCLIC BASES | METABASIS THERAPEUTICS, INC. (US) | 1999-01-26 | — | — | US | disclosed |
| EP-0873340-A1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | Abbott Laboratories (US) | 1998-10-28 | — | — | EP | disclosed |
| WO-1998046605-A1 | 5,7-DISUBSTITUTED 4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS AND THEIR USE AS ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046604-A1 | 5,6,7-TRISUBSTITUTED-4-AMINOPYRIDOL[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
| WO-1998046603-A1 | 6,7-DISUBSTITUTED-4-AMINOPYRIDO[2,3-D]PYRIMIDINE COMPOUNDS | ABBOTT LABORATORIES (US) | 1998-10-22 | — | — | WO | disclosed |
| US-5824657-A | ANTICARCINOGENIC AGENTS, SKIN DISORDERS AND PSORIASIS | CUBIST PHARMACEUTICALS, INC. (US) | 1998-10-20 | — | — | US | disclosed |
| US-5795977-A | Water soluble adenosine kinase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 1998-08-18 | — | — | US | disclosed |
| US-5773423-A | XANTHINE RIBOSIDES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1998-06-30 | — | — | US | disclosed |
| US-5773424-A | PARASITICIDE | RESEARCH CORPORATION TECHNOLOGIES, INC. (US) | 1998-06-30 | — | — | US | disclosed |
| US-5763596-A | PYROLO PYRIMIDINE AND PYRAZOLO PYRIMIDINE COMPOUMDS; TREATMENT OF CARDIOVASCULAR AND BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS | METABASIS THERAPEUTICS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| US-5763597-A | Orally active adenosine kinase inhibitors | METABASIS THERAPEUTICS, INC. (US) | 1998-06-09 | — | — | US | disclosed |
| EP-0836613-A1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-22 | — | — | EP | disclosed |
| EP-0832092-A1 | ORALLY ACTIVE ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| EP-0832091-A1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1998-04-01 | — | — | EP | disclosed |
| US-5726302-A | SUBSTITUTED 4-AMINO PYRROLO(2,3-D) PYRIMIDINE AND PYRAZOLO(3,4-D) PYRIMIDINE NUCLEOSIDE ANALOGS | GENSIA INC. (US) | 1998-03-10 | — | — | US | disclosed |
| US-5721356-A | SUBSTITUTED 5-ARYLPYRROLO(2,3-D)PYRIMIDINE OR 3-ARYLPYRAZOLO(3,4-D)PYRIMIDINE; CARDIOVASCULAR DISORDERS, BRAIN DISORDERS, ANTIINFLAMMATORY AGENTS | GENSIA, INC. (US) | 1998-02-24 | — | — | US | disclosed |
| EP-0682519-A4 | ADENOSINE KINASE INHIBITORS. | GENSIA INC (US) | 1997-12-17 | — | — | EP | disclosed |
| US-5674998-A | FOR TREATING CARDIOVASCULAR OR BRAIN DISORDERS, OR AS ANTIINFLAMMATORY AGENT | GENSIA INC. (US) | 1997-10-07 | — | — | US | disclosed |
| US-5665721-A | ADENOSINE KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1997-09-09 | — | — | US | disclosed |
| US-5658889-A | ADMINISTERING 5-AMINO-4-IMIDAZLECARBOXAMIDE RIBOSIDE WHICH BINDS ADENOSINE MONOPHOSPHATE SITE OF FRUCTOSE-1,6-DIPHOSPHATASE | GENSIA PHARMACEUTICALS, INC. (US) | 1997-08-19 | — | — | US | disclosed |
| US-5646128-A | TREATING INFLAMMATION, SEPSIS, SEPTIC SHOCK, BURNS | GENSIA, INC. (US) | 1997-07-08 | — | — | US | disclosed |
| EP-0755255-A1 | TREATMENT OF TOXOPLASMOSIS | UNIVERSITY OF ALABAMA, BIRMINGHAM RESEARCH FOUNDATION (US) | 1997-01-29 | — | — | EP | disclosed |
| WO-1996040686-A1 | HETEROCYCLIC SUBSTITUTED CYCLOPENTANE COMPOUNDS | ABBOTT LABORATORIES (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040705-A1 | C-4' MODIFIED ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040707-A1 | WATER-SOLUBLE ADENOSINE KINASE INHIBITORS | GENSIA SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996040706-A1 | ORALLY ACTIVE ADENOSINE KINASE INHIBITORS | GENSIA-SICOR (US) | 1996-12-19 | — | — | WO | disclosed |
| WO-1996018398-A1 | TREATMENT OF TOXOPLASMOSIS | THE UNIVERSITY OF ALABAMA AT BIRMINGHAM RESEARCH FOUNDATION (US) | 1996-06-20 | — | — | WO | disclosed |
| EP-0715523-A1 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1996-06-12 | — | — | EP | disclosed |
| EP-0708781-A1 | A 3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, Department of Health and Human Services (US) | 1996-05-01 | — | — | EP | disclosed |
| US-5506347-A | ADENOSINE KINASE INHIBITOR | GENSIA, INC. (US) | 1996-04-09 | — | — | US | disclosed |
| EP-0684953-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1995-12-06 | — | — | EP | disclosed |
| EP-0682519-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1995-11-22 | — | — | EP | disclosed |
| WO-1995007718-A2 | PURINE NUCLEOSIDE PHOSPHORYLASE GENE THERAPY FOR HUMAN MALIGNANCY | THE UAB RESEARCH FOUNDATION (US) | 1995-03-23 | — | — | WO | disclosed |
| WO-1995002604-A1 | A3 ADENOSINE RECEPTOR AGONISTS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1995-01-26 | — | — | WO | disclosed |
| EP-0427799-B1 | METHOD AND COMPOUNDS FOR AICA RIBOSIDE DELIVERY AND FOR LOWERING BLOOD GLUCOSE | GENSIA PHARMA (US) | 1994-11-30 | — | — | EP | disclosed |
| WO-1994017803-A9 | ADENOSINE KINASE INHIBITORS | — | 1994-09-29 | — | — | WO | disclosed |
| WO-1994018215-A1 | ADENOSINE KINASE INHIBITORS COMPRISING LYXOFURANOSYL DERIVATIVES | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994017803-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1994-08-18 | — | — | WO | disclosed |
| WO-1994006438-A1 | ADENOSINE ANALOGUES AND METHOD OF INCREASING ADENOSINE RELEASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 1994-03-31 | — | — | WO | disclosed |
| WO-1994004194-A1 | NUCLEIC ACID RECOGNITION AND TRANSPORT | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1994-03-03 | — | — | WO | disclosed |
| WO-1992012718-A1 | ADENOSINE KINASE INHIBITORS | GENSIA, INC. (US) | 1992-08-06 | — | — | WO | disclosed |
| EP-0496617-A1 | Adenosine kinase inhibitors | GENSIA, INC. (US) | 1992-07-29 | — | — | EP | disclosed |
| EP-0037310-B1 | SUBSTITUTED DEOXYADENOSINE DERIVATIVES | MERRELL TORAUDE ET COMPAGNIE (FR) | 1984-05-09 | — | — | EP | disclosed |
| US-4374128-A | TREATING RAPID CELL PROLIFERATION | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-02-15 | — | — | US | disclosed |
| EP-0037310-A1 | Substituted deoxyadenosine derivatives | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-10-07 | — | — | EP | disclosed |
| EP-0037310-A1 | Substituted deoxyadenosine derivatives | MERRELL TORAUDE ET COMPAGNIE (FR) | 1981-10-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (20 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150322107-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | SAMSN1, TIPARP, SPR | DOT1L 3457/4885ADORA3 1318/4885DPP4 3850/4885 |
| US-20130324461-A1 | METHODS AND COMPOSITIONS FOR PREVENTING OR TREATING OBESITY | ADORA2A, ADORA3, ADORA1 | DOT1L 3275/4885ADORA3 2/4885DPP4 1538/4885 |
| US-20080070860-A1 | Purine nucleoside analogs that are selective ligands of the purine salvage pathway enzyme adenosine phosphorylase (AP) found in bacteria and protozoa; 2-chloro-5'-deoxyadenosine; 2-chloro-6-methylpurine-5'-deoxyriboside | PNP, MTAP, TYMP | DOT1L 4452/4885ADORA3 30/4885DPP4 365/4885 |
| US-20070265223-A1 | COMPOSITIONS AND METHODS OF ENHANCING SURVIVABILITY AND REDUCING INJURY OF CELLS, TISSUES, ORGANS, AND ORGANISMS UNDER HYPOXIC OR ISCHEMIC CONDITIONS | ADORA2A, ADORA2B, ADORA1 | DOT1L 4041/4885ADORA3 5/4885DPP4 2005/4885 |
| US-20160067271-A1 | Methods And Compositions For Preventing Or Treating Obesity | ADORA2A, ADORA3, ADORA1 | DOT1L 3275/4885ADORA3 2/4885DPP4 1538/4885 |
| US-20030187276-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885ADORA3 619/4885DPP4 3725/4885 |
| US-20150359761-A1 | METHODS AND COMPOSITIONS FOR TREATMENT OF DEMYELINATING DISEASES | SRM, PMP22, SMS | DOT1L 2184/4885ADORA3 1453/4885DPP4 3892/4885 |
| US-10085955-B2 | Methods and compositions for treatment of demyelinating diseases | SRM, PMP22, SMS | DOT1L 2184/4885ADORA3 1453/4885DPP4 3892/4885 |
| US-20100317832-A1 | AZIRIDINE ALDEHYDES, AZIRIDINE-CONJUGATED AMINO DERIVATIVES, AZIRIDINE-CONJUGATED BIOMOLECULES AND PROCESSES FOR THEIR PREPARATION | QDPR, VIP, AAAS | DOT1L 3370/4885ADORA3 442/4885DPP4 398/4885 |
| US-20050176828-A1 | Hydrophobic polyamine analogs and methods for their use | SRM, SMS, HNMT | DOT1L 595/4885ADORA3 619/4885DPP4 3725/4885 |
| US-20070060600-A1 | 4-Anilinequinazolines with adenosine-kiase inhibitor properties | ADK, AK1, ADORA3 | DOT1L 2827/4885ADORA3 3/4885DPP4 692/4885 |
| US-20100233743-A1 | BISUBSTRATE FLUORESCENT PROBE BINDING TO PROTEIN KINASES | ADK, PRKCH, DMPK | DOT1L 2038/4885ADORA3 425/4885DPP4 2675/4885 |
| US-20130331351-A1 | NOVEL ANTIBACTERIAL COMPOUNDS | FPR3, ANTXR2, MRPL21 | DOT1L 2372/4885ADORA3 439/4885DPP4 454/4885 |
| US-20050214901-A1 | Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof | PNP, UPP1, TYMP | DOT1L 4794/4885ADORA3 974/4885DPP4 2366/4885 |
| US-20170290788-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | DOT1L 4266/4885ADORA3 2606/4885DPP4 3132/4885 |
| US-20110112199-A1 | PHARMACEUTICAL FOR ORAL DELIVERY COMPRISING MGBG AND METHODS OF TREATING DISEASE | BPGM, PYGB, EDNRB | DOT1L 4266/4885ADORA3 2606/4885DPP4 3132/4885 |
| US-20050245615-A1 | Composition containing polyamine transport inhibitor and use thereof | SLC7A1, SRM, SLC16A1 | DOT1L 862/4885ADORA3 519/4885DPP4 3956/4885 |
| US-20150323542-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | SAMSN1, TIPARP, SPR | DOT1L 3457/4885ADORA3 1318/4885DPP4 3850/4885 |
| US-20120295283-A1 | FLUORESCENT MOLECULAR PROBES FOR USE IN ASSAYS THAT MEASURE TEST COMPOUND COMPETITIVE BINDING WITH SAM-UTILIZING PROTEINS | SAMSN1, TIPARP, SPR | DOT1L 3457/4885ADORA3 1318/4885DPP4 3850/4885 |
| US-20100254965-A1 | Adenosine Signaling in Diagnosis, Treatment, and Prevention of Priapism and Erectile Dysfunction | ADORA2A, PDE7A, PDE3A | DOT1L 4513/4885ADORA3 5/4885DPP4 2794/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.